|
|
Vaccine Detail
|
Pfs25-IMX313/Matrix-M |
| Vaccine Information |
- Vaccine Name: Pfs25-IMX313/Matrix-M
- Type: protein-nanoparticle vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Antigen: Pfs25: post-fertilization antigen, three potential N-linked glycosylation sites (112, 165 and 187) mutated. Involved in ookinete formation, survival in the mosquito midgut, and a possible role in parasite traversal of the mid-gut epithelium. (Mulamba et al., 2022)
- Pfs25 from P. falciparum 3D7
gene engineering:
- Type: Recombinant protein preparation
- Description: Pfs25 antigen is genetically fused to the IMX313 oligomerization domain (Mulamba et al., 2022)
- Detailed Gene Information: Click Here.
- Adjuvant: Matrix-M vaccine adjuvant
- VO ID: VO_0005206
- Description: A potent saponinbased adjuvant, comprising partially purifed extracts of the bark of the Quillaja saponaria Molina tree, phosphatidylcholine and cholesterol. Enhance immune responses (Mulamba et al., 2022)
- Immunization Route: Intramuscular injection (i.m.)
- Description: **Mechanism: Human get vaccinated --> Human produce antibodies --> mosquitoes take up antibodies --> reduce parasite fertilization in mosquitoes (Mulamba et al., 2022)
|
| References |
Mulamba et al., 2022: Mulamba C, Williams C, Kreppel K, Ouedraogo JB, Olotu AI. Evaluation of the Pfs25-IMX313/Matrix-M malaria transmission-blocking candidate vaccine in endemic settings. Malaria journal. 2022; 21(1); 159. [PubMed: 35655174].
|
|
